Maternal and neonatal outcome after the use of g-csf for cancer treatment during pregnancy

Claudia Berends, Charlotte Maggen, Christianne A.R. Lok, Mathilde van Gerwen, Ingrid A. Boere, Vera E.R.A. Wolters, Kristel Van Calsteren, Heidi Segers, Marry M. van den Heuvel-Eibrink, Rebecca C. Painter, Mina Mhallem Gziri, Frédéric Amant

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

7 Citaten (Scopus)


Data on the use of Granulocyte colony-stimulating factor (G-CSF) in pregnant cancer patients are scarce. The International Network of Cancer, Infertility and Pregnancy (INCIP) reviewed data of pregnant patients treated with chemotherapy and G-CSF, and their offspring. Among 2083 registered patients, 42 pregnant patients received G-CSF for the following indications: recent chemotherapy induced febrile neutropenia (5; 12%), dose dense chemotherapy (28, 67%), poly chemotherapy (7, 17%), or prevention of neutropenia at delivery (2; 5%). Among 24 women receiving dose dense chemotherapy, three (13%) patients recovered from asymptomatic neutropenia within 5 days. One patient developed pancytopenia following polychemotherapy after which the pregnancy was complicated by chorioamnionitis and intrauterine death. Nineteen singleton livebirths (49%) were born preterm. Sixteen neonates (41%) were admitted to the Neonatal Intensive care Unit (NICU). No neonatal neutropenia occurred. Two neonates had congenital malformations. Out of 21 children in follow-up, there were four children with a motor development delay and two premature infants had a delay in cognitive development. In conclusion, the rate of maternal and neonatal complications are similar to those described in (pregnant) women treated with chemotherapy. Due to small numbers and limited follow-up, rare or delayed effects among offspring exposed to G-CSF in utero cannot be ruled out yet.

Originele taal-2Engels
Pagina's (van-tot)1-12
Aantal pagina's12
Nummer van het tijdschrift6
StatusGepubliceerd - 2 mrt. 2021


Duik in de onderzoeksthema's van 'Maternal and neonatal outcome after the use of g-csf for cancer treatment during pregnancy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit